Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00186238 | High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma | completed | Phase 2 | 300 | Stanford UniversityOTHER | 1 | Sep 14, 2010 | clinicaltrials |
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 |
| clinicaltrials |
| NCT00794261 | Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma(PALM) | completed | Phase 2 | 150 | Centre Leon BerardOTHER | 1 | Jul 8, 2010 | clinicaltrials |
| NCT00083538 | Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally | completed | Phase 2 | 40 | University of ArkansasOTHER | 1 | Jul 7, 2010 | clinicaltrials |
| NCT00083408 | Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide | completed | Phase 2 | 20 | University of ArkansasOTHER | 1 | Jul 5, 2010 | clinicaltrials |
| NCT00081757 | An Open Protocol for the Compassionate Use of Thalidomide | completed | Phase 1 / Phase 2 | 250 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00083577 | Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma | completed | Phase 2 | 250 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00083681 | DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse | completed | Phase 2 | 180 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00083902 | Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy | completed | Phase 2 | 190 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00193557 | Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 1 | Jun 29, 2010 | clinicaltrials |
| NCT00508209 | Bortezomib and High-dose Melphalan at Myeloma Relapse | unknown | Phase 2 | 50 | Nordic Myeloma Study GroupOTHER | 3 | Jun 22, 2010 | clinicaltrials |
| NCT00275262 | A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation | terminated | Phase 2 | 25 | AbbottINDUSTRY | 1 | May 6, 2010 | clinicaltrials |
| NCT01085058 | Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy(CU01) | completed | Phase 2 / Phase 3 | 169 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 0 | Mar 11, 2010 | clinicaltrials |
| NCT00304590 | Study of XL999 in Patients With Multiple Myeloma | terminated | Phase 2 | 4 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT00124813 | Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma | unknown | Phase 2 | 80 | University Hospital, BonnOTHER | 1 | Feb 2, 2010 | clinicaltrials |
| NCT00229203 | A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma | completed | Phase 2 | 51 | PharmaMarINDUSTRY | 1 | Dec 24, 2009 | clinicaltrials |
| NCT00051116 | A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma | completed | Phase 2 | 100 | Celgene CorporationINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00391157 | VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma | completed | Phase 2 | 40 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00186316 | Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Stanford UniversityOTHER | 1 | Aug 25, 2009 | clinicaltrials |
| NCT00327249 | Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | — | AmpliMed CorporationINDUSTRY | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00598624 | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)(AlloTreo) | unknown | Phase 2 | 175 | IRCCS San RaffaeleOTHER | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00306813 | Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of WuerzburgOTHER | 1 | Aug 4, 2009 | clinicaltrials |
| NCT00436059 | The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer) | completed | Phase 2 | 20 | Vejle HospitalOTHER | 1 | Jul 8, 2009 | clinicaltrials |
| NCT00781170 | Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma | completed | Phase 2 | 20 | Universitätsklinikum Hamburg-EppendorfOTHER | 0 | May 28, 2009 | clinicaltrials |
| NCT00036023 | Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies | completed | Phase 2 | — | AmgenINDUSTRY | 0 | May 11, 2009 | clinicaltrials |
| NCT00592579 | A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma | completed | Phase 2 | 60 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00516152 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 26, 2009 | clinicaltrials |
| NCT00193544 | Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | Jan 23, 2009 | clinicaltrials |
| NCT00039754 | A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | — | Poniard PharmaceuticalsINDUSTRY | 0 | Jan 21, 2009 | clinicaltrials |
| NCT00804947 | Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen | unknown | Phase 2 | 50 | Fundacion Para La Investigacion Hospital La FeOTHER | 1 | Dec 9, 2008 | clinicaltrials |
| NCT00352742 | A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | AttenuonINDUSTRY | 1 | Oct 28, 2008 | clinicaltrials |
| NCT00415987 | Hematopoietic Stem Cell Transplantation in Myeloma | unknown | Phase 2 / Phase 3 | — | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jun 20, 2008 | clinicaltrials |
| NCT00702247 | Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi) | unknown | Phase 2 | — | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jun 20, 2008 | clinicaltrials |
| NCT00320476 | VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates | completed | Phase 2 | 35 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00349115 | TCD Followed by autoSCT for Newly Diagnosed MM Patients | unknown | Phase 2 | 43 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00001750 | Comparing Treatments for Multiple Myeloma | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00304720 | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | unknown | Phase 2 | 40 | Colorado Blood Cancer InstituteOTHER | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00116441 | Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00086216 | Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 30 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00165347 | Protein Tyrosine Kinases (PTK) in Multiple Myeloma | completed | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00143884 | Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood | terminated | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 23, 2007 | clinicaltrials |
| NCT00327314 | Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma | unknown | Phase 2 | 100 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Dec 28, 2006 | clinicaltrials |
| NCT00399867 | Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma. | completed | Phase 2 | 30 | Ludwig-Maximilians - University of MunichOTHER | 0 | Dec 20, 2006 | clinicaltrials |
| NCT00358020 | Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients | completed | Phase 2 | 30 | University of Turin, ItalyOTHER | 1 | Dec 4, 2006 | clinicaltrials |
| NCT00396045 | Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | University of Turin, ItalyOTHER | 1 | Nov 30, 2006 | clinicaltrials |
| NCT00048464 | T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant | unknown | Phase 1 / Phase 2 | 35 | Xcyte TherapiesINDUSTRY | 1 | Nov 7, 2006 | clinicaltrials |
| NCT00300664 | A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. | completed | Phase 2 / Phase 3 | 150 | Royal Marsden NHS Foundation TrustOTHER | 0 | Oct 13, 2006 | clinicaltrials |
| NCT00382694 | Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients | unknown | Phase 2 | 80 | Nordic Myeloma Study GroupOTHER | 1 | Sep 29, 2006 | clinicaltrials |
| NCT00378755 | Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM | unknown | Phase 2 | 62 | Korean Multiple Myeloma Working PartyOTHER | 1 | Sep 22, 2006 | clinicaltrials |
| NCT00337506 | Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | terminated | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Jun 16, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Sep 14, 2010source: clinicaltrials